Paroxetine-mediated GRK2 inhibition is a disease-modifying treatment for osteoarthritis
Elijah L. Carlson, Vengadeshprabhu Karuppagounder, William J. Pinamont, Natalie K. Yoshioka, Adeel Ahmad, Eric M. Schott, Heather K. Le Bleu, Michael J. Zuscik, Reyad A. Elbarbary, Fadia Kamal
Dive into the research topics of 'Paroxetine-mediated GRK2 inhibition is a disease-modifying treatment for osteoarthritis'. Together they form a unique fingerprint.